Long-Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis.

What was studied

This was an interim look at ADHERE+, an open-label extension of the ADHERE trial. ADHERE tested efgartigimod PH20 under the skin once weekly in CIDP. People who took part in ADHERE could move on to ADHERE+. There they got efgartigimod. The main goal was long-term safety and tolerability. The team also tracked disability scores and grip strength through week 36.

What they found

At the data cut-off, 228 of 229 people moved on to ADHERE+. Longer use of the drug did not raise the rate or severity of side effects. Infections were few, whatever the IgG level. People who responded in stage A reported lasting gains. The aINCAT score fell by 1.2 points. The I-RODS score rose by 8.8 points. Grip strength rose by 17.5 kPa. This held whatever the stage B treatment.

What it means for patients

The authors say long-term treatment was well tolerated. They say gains in disability and strength were seen across tests. They say the gains grew over time.

Why it is not certain yet

These are interim results. The extension was open-label, so everyone knew the treatment. The gains are for people who responded in stage A. The longest exposure was 187.3 weeks, and the mean was 58.0 weeks.

Source

Long-Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.